Zobrazeno 51 - 60
of 133
pro vyhledávání: '"Enrique Zudaire"'
Autor:
Samir Parekh, Adam B. Cohen, Bertrand Arnulf, Deepu Madduri, Bianca Santomasso, Yunsi Olyslager, Maria-Victoria Mateos, Marlene Carrasco-Alfonso, Carolyn C. Jackson, Enrique Zudaire, Jaime Gállego Pérez-Larraya, Muhammad Akram, Dong Geng, Niels W.C.J. van de Donk, Andrzej Jakubowiak, Helen Varsos, Kevin C. De Braganca, Nikoletta Lendvai, Hermann Einsele, Claire Li
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S421-S422
Context Cilta-cel, a chimeric antigen receptor T (CAR-T) cell therapy with two B-cell maturation antigen (BCMA)-targeting single-domain antibodies demonstrated efficacy in relapsed/refractory multiple myeloma (MM). Objectives To describe mitigation a
Autor:
Sandy W. Wong, Shambavi Richard, Yi Lin, Deepu Madduri, Carolyn C. Jackson, Enrique Zudaire, Vadim Romanov, Michael Trigg, Martin Vogel, Ashraf Garrett, Lisa Hullinger, Tonia Nesheiwat, Tom Martin III, Sundar Jagannath
Publikováno v:
Transplantation and Cellular Therapy. 28:S172
Autor:
Sen Hong Zhuang, Elizabeth O'Donnell, Syed Rizvi, Saad Z. Usmani, Myo Htut, Jenna D. Goldberg, Jesus G. Berdeja, Xiaoling Wu, Abhinav Deol, David Avigan, Andrzej Jakubowiak, Jordan M. Schecter, Dong Geng, Muhammad Akram, Parameswaran Hari, William Deraedt, Indrajeet Singh, Farah Hossain, Deepu Madduri, Sundar Jagannath, Tzu-Min Yeh, Mounzer Agha, Jeffrey R. Infante, Carolyn C. Jackson, Nikhil C. Munshi, Alicia J. Allred, Frank Fan, Marlene J Carrasco-Alfonso, A. Keith Stewart, Arnob Banerjee, Yi Lin, Enrique Zudaire, Yunsi Olyslager, Alexander M. Lesokhin, Adam D. Cohen, Thomas Martin
Publikováno v:
Lancet (London, England). 398(10297)
Summary Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients wi
Autor:
Charles G, Drake, Russell K, Pachynski, Sumit K, Subudhi, Douglas G, McNeel, Emmanuel S, Antonarakis, Todd M, Bauer, Peter, Lauer, Dirk, Brockstedt, Daniel, Patricia, Mark, Wade, Enrique, Zudaire, Nibedita, Bandyopadhyay, Dolly A, Parasrampuria, Suzette, Girgis, Gary E, Mason, Roland E, Knoblauch, Nicole, Stone, Jeffrey R, Infante, Marco M, Gottardis, Lawrence, Fong
Publikováno v:
Prostate cancer and prostatic diseases. 25(2)
The safety and immunogenicity of JNJ-64041809 (JNJ-809), a live-attenuated, double-deleted Listeria monocytogenes (LADD Lm)-based immunotherapy targeting 4 relevant prostate cancer antigens, was evaluated in a phase 1 study in patients with metastati
Autor:
Jenna D. Goldberg, Enrique Zudaire, Alicia J. Allred, Jordan M. Schecter, Marlene J. Carrasco, Farah Hossain, Tzu-Min Yeh, Saad Z. Usmani, Sundar Jagannath, Yi Lin, Thomas Martin, Jesus G. Berdeja, Muhammad Akram, Xiaoling Wu, Jagoda Jasielec, Vickie Wang, Andrzej Jakubowiak, Dong Geng, Indrajeet Singh, Mounzer Agha, Carolyn C. Jackson, Deepu Madduri, Adam D. Cohen, A. Keith Stewart, William Deraedt, Arnob Banerjee, Yunsi Olyslager
Publikováno v:
Transplantation and Cellular Therapy. 27:S43-S44
Background: The phase 1b/2 CARTITUDE-1 study (NCT03548207) is evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells), a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-
Autor:
Julie R, Brahmer, Melissa L, Johnson, Manuel, Cobo, Santiago, Viteri, Juan Coves, Sarto, Ammar, Sukari, Mark M, Awad, Ravi, Salgia, Vali A, Papadimitrakopoulou, Arun, Rajan, Nibedita, Bandyopadhyay, Alicia J, Allred, Mark, Wade, Gary E, Mason, Enrique, Zudaire, Roland E, Knoblauch, Nicole, Stone, Matthew V, Lorenzi, Raffit, Hassan
Publikováno v:
JTO Clinical and Research Reports
Introduction JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted Listeria monocytogenes–based immunotherapy expressing human mesothelin. JNJ-757 was evaluated in patients with advanced NSCLC as monotherapy (phase 1) and in combination with
Autor:
Xiaoyan M. Zhang, Enrique Zudaire, Brad St. Croix, Karen Morris, Jennifer Hwang, Dean Welsch, Guojun Yu, James M. Dunleavey, Yang Feng, Steven Seaman, Diana C. Haines, Decrescenzo Gary A, Saurabh Saha, Kuo Sheng Hsu, Zhongyu Zhu, Mary Beth Hilton, Christopher S. Szot, Dimiter S. Dimitrov, Deborah A. Swing, Yanping Wang, Amit Chaudhary, Holly Morris
Publikováno v:
Journal of Clinical Investigation. 128:2927-2943
Although nonmalignant stromal cells facilitate tumor growth and can occupy up to 90% of a solid tumor mass, better strategies to exploit these cells for improved cancer therapy are needed. Here, we describe a potent MMAE-linked antibody-drug conjugat
Autor:
Muhammad Akram, Pieter Sonneveld, Mounzer Agha, Michel Delforge, Sonja Zweegman, Martin Vogel, Tessa Kerre, Jordan M. Schecter, Tonia Nesheiwat, Adam D. Cohen, Kevin C. De Braganca, Sébastien Anguille, Yael C Cohen, Niels W.C.J. van de Donk, Wilfried W. H. Roeloffzen, Lida Bubuteishvili Pacaud, Jens Hillengass, Liwei Wang, Christina Corsale, Dong Geng, Helen Varsos, Enrique Zudaire
Publikováno v:
Blood. 138:2910-2910
Introduction: Patients (pts) with multiple myeloma (MM) who experience early clinical relapse, defined as disease progression ≤12 mo after autologous stem cell transplantation (ASCT) or start of initial treatment (tx), have median overall survival
Autor:
Carolyn C. Jackson, Jesus G. Berdeja, William Deraedt, Andrzej Jakubowiak, Saad Z. Usmani, Sundar Jagannath, Jordan M. Schecter, Yunsi Olyslager, Mounzer Agha, Alicia J. Allred, Dong Geng, Thomas Martin, Arnob Banerjee, Deepu Madduri, Enrique Zudaire, Yi Lin, Changwei Zhou, Parameswaran Hari, Lida Bubuteishvili Pacaud, Tzu-Min Yeh, Adam D. Cohen
Publikováno v:
Blood. 138:3938-3938
Introduction: Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell (CAR-T) therapy with 2 B-cell maturation antigen (BCMA)-targeting single-domain antibodies, is being evaluated in patients (pts) with relapsed/refractory multiple
Autor:
Saad Z. Usmani, David Avigan, A. Keith Stewart, Deepu Madduri, Andrzej Jakubowiak, Alicia J. Allred, Yunsi Olyslager, Carolyn C. Jackson, Thomas Martin, Tzu-Min Yeh, Changwei Zhou, Adam D. Cohen, Jordan M. Schecter, Sundar Jagannath, Nikhil C. Munshi, Parameswaran Hari, Mounzer Agha, Arnob Banerjee, Elizabeth O'Donnell, Enrique Zudaire, Jenna D. Goldberg, Alexander M. Lesokhin, Abhinav Deol, Jesus G. Berdeja, Lida Bubuteishvili Pacaud, Myo Htut, Yi Lin, William Deraedt
Publikováno v:
Blood. 138:549-549
Introduction: Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen (BCMA) targeting single-domain antibodies, demonstrated early, deep, and durable responses in the phase 1b/2 CART